Literature DB >> 8959322

Can hematuria be a predictor as well as a symptom or sign of bladder cancer?

G D Friedman1, P R Carroll, E V Cattolica, R A Hiatt.   

Abstract

In a case-control study of urinalysis screening in the prevention of death from bladder cancer, hematuria was present in a higher proportion of cases than controls as long as five or six years before the diagnostic evaluation that led to the diagnosis of bladder cancer. In a separate cohort study data base that permitted the follow-up of 1046 persons with a physician's diagnosis of hematuria, 11 cases of bladder cancer were diagnosed more than two (mean 7.4) years after the hematuria diagnosis (4.3 cases expected; age-sex standardized morbidity ratio, 2.5; 95% confidence interval, 1.3-4.5). Bladder cancer was ruled out initially by cystoscopy in 8 of the 11 cases. Although we cannot be certain that preexisting bladder cancer or bladder cancer risk factors did not cause the bleeding, we hypothesize that hematuria can be a predictor as well as a manifestation of bladder cancer, based on a tendency for bladder mucosa with premalignant changes to bleed. The implications for screening and clinical practice remain to be determined.

Entities:  

Mesh:

Year:  1996        PMID: 8959322

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

1.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

2.  Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria.

Authors:  Joerg Hennenlotter; Severine Huber; Tilman Todenhöfer; Ursula Kuehs; David Schilling; Stefan Aufderklamm; Georgios Gakis; Christian Schwentner; Arnulf Stenzl
Journal:  Adv Urol       Date:  2011-11-22

3.  Ovarian cancer histology-specific incidence trends in Canada 1969-1993: age-period-cohort analyses.

Authors:  J Zhang; A M Ugnat; K Clarke; Y Mao
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

4.  Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'.

Authors:  Agata Ptaszynska; Samuel M Cohen; Edward M Messing; Timothy P Reilly; Eva Johnsson; Kristina Johnsson
Journal:  Diabetes Ther       Date:  2015-09-01       Impact factor: 2.945

5.  Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer.

Authors:  Ding-Zuan Zhang; Kin-Mang Lau; Eddie S Y Chan; Gang Wang; Cheuk-Chun Szeto; Kenneth Wong; Richard K W Choy; Chi-Fai Ng
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.